Literature DB >> 24043599

Changes in prevalence and clinical characteristics of cervical cancer in the People's Republic of China: a study of 10,012 cases from a nationwide working group.

Shuang Li1, Ting Hu, Weiguo Lv, Hang Zhou, Xiong Li, Ru Yang, Yao Jia, Kecheng Huang, Zhilan Chen, Shaoshuai Wang, Fangxu Tang, Qinghua Zhang, Jian Shen, Jin Zhou, Ling Xi, Dongrui Deng, Hui Wang, Shixuan Wang, Xing Xie, Ding Ma.   

Abstract

PURPOSE: About one-third of the world's total annual new cervical cancer cases are found in the People's Republic of China. We investigate the prevalence and clinical characteristics of cervical cancer cases in the People's Republic of China over the past decade.
METHOD: A total of 10,012 hospitalized patients with cervical cancer from regions nationwide were enrolled from 2000 to 2009. Demographic and clinical characteristics, therapeutic strategies, and outcomes were analyzed.
RESULTS: The mean age at diagnosis of all cervical cancer patients was 44.7 ± 9.5 years, which is 5-10 years younger than mean ages reported before 2000 in the People's Republic of China. The age distribution showed 16.0% of patients were ≤35 years old, 41.7% were 35-45 years old, and 41.7% were >45 years old. Early stage diagnoses were most prevalent: 57.3% were stage I, 33.9% were stage II, and 4.3% were stage III or IV. Most patients (83.9%) were treated with surgery, and only 9.5% had radiotherapy alone. Among 8,405 patients treated with surgery, 68.6% received adjuvant treatments, including chemotherapy (20.9%), radiotherapy (26.0%), and chemoradiotherapy (21.9%). Among stage IA patients, 16.0% were treated with corpus uteri preservation. The proportion of ovarian preservation was 42.0%.
CONCLUSIONS: Cervical cancer cases in the People's Republic of China show increasing prevalence in young patients and at early stages. In the past 10 years, surgery has become the dominant treatment and is increasingly combined with adjuvant chemotherapy for patients with stages I and II. Conservative surgical approaches are reasonable options for genital organ preservation in selected patients.

Entities:  

Keywords:  Cervical cancer; Clinical feature; Surgery; Survival rate; Therapeutic strategies

Mesh:

Year:  2013        PMID: 24043599      PMCID: PMC3805152          DOI: 10.1634/theoncologist.2013-0123

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  39 in total

1.  Postoperative radiotherapy for uterine cervical cancer: results of the 1995-1997 patterns of care process survey in Japan.

Authors:  Takafumi Toita; Norio Mitsuhashi; Teruki Teshima; Katsuya Maebayashi; Katsumasa Nakamura; Yutaka Takahashi; Toshihiko Inoue
Journal:  Jpn J Clin Oncol       Date:  2004-02       Impact factor: 3.019

2.  Treatment and survival in 631 patients with invasive carcinoma of the cervix.

Authors:  C Gad
Journal:  Br J Obstet Gynaecol       Date:  1976-07

3.  Carcinoma cervicis uteri. Treatment results from the period 1953--1968.

Authors:  B Ptácková
Journal:  Neoplasma       Date:  1976       Impact factor: 2.575

4.  Diagnostic and therapeutic aspects of cervical carcinoma. Based on the material of 991 cases.

Authors:  S Ruponen
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1977

5.  Carcinoma of the uterine cervix. Results of treatment in 2 248 cases.

Authors:  J Jimenez; J Alert; L Beldarrain; J Montalvo; C Roca
Journal:  Acta Radiol Oncol Radiat Phys Biol       Date:  1979

6.  Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma.

Authors:  M S Piver; W S Chung
Journal:  Obstet Gynecol       Date:  1975-11       Impact factor: 7.661

7.  Cervical cancer practice patterns and appropriateness of therapy.

Authors:  E Howell; Y T Chen; M Moradi; J Concato
Journal:  Am J Obstet Gynecol       Date:  2000-08       Impact factor: 8.661

8.  Tumours in Iceland. 5. Malignant tumours of the cervix uteri. Histological types, clinical stages and the effect of mass screening.

Authors:  G Geirsson; G Jóhannesson; H Tulinius
Journal:  Acta Pathol Microbiol Immunol Scand A       Date:  1982-03

9.  Cervical cancer in Finland and South Wales: implications of end results data on the natural history.

Authors:  M Hakama; R West
Journal:  J Epidemiol Community Health       Date:  1980-03       Impact factor: 3.710

10.  Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.

Authors:  Patricia J Eifel; Kathryn Winter; Mitchell Morris; Charles Levenback; Perry W Grigsby; Jay Cooper; Marvin Rotman; David Gershenson; David G Mutch
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

View more
  43 in total

1.  Epidemiology and genotype distribution of high risk human papillomavirus in population of hospital opportunistic screening.

Authors:  Ying-Qiao Liu; Xin He; Sha-Sha Xu; Jiu-Xin Qu; Yue Wang; Xiao-Li Diao; Jun Liu; Shu-Zhen Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 2.  Current issues facing the introduction of human papillomavirus vaccine in China and future prospects.

Authors:  Li Ping Wong; Liyuan Han; Hui Li; Jinshun Zhao; Qinjian Zhao; Gregory D Zimet
Journal:  Hum Vaccin Immunother       Date:  2019-07-16       Impact factor: 3.452

3.  Factors Associated with Delayed Reporting of Invasive Carcinoma Cervix in a Rural Tertiary Care Center.

Authors:  K R Radha; R P Reena
Journal:  J Obstet Gynaecol India       Date:  2015-10-10

4.  Prevalence of and risk factors for high-risk human papillomavirus infection: a population-based study from Hetian, Xinjiang, China.

Authors:  Mayinuer Niyazi; Sulaiya Husaiyin; Lili Han; Huduyum Mamat; Kundus Husaiyin; Lin Wang
Journal:  Bosn J Basic Med Sci       Date:  2016-01-01       Impact factor: 3.363

5.  Oncogenic role of Tc17 cells in cervical cancer development.

Authors:  Zun-Sheng Zhang; Ying Gu; Bing-Gang Liu; Hong Tang; Yu Hua; Jun Wang
Journal:  World J Clin Cases       Date:  2020-01-06       Impact factor: 1.337

6.  Pilot in vitro and in vivo study on a mouse model to evaluate the safety of transcutaneous low-frequency electrical nerve stimulation on cervical cancer patients.

Authors:  Shiyan Wang; Xiuli Sun; Wenjin Cheng; Jue Zhang; Jianliu Wang
Journal:  Int Urogynecol J       Date:  2018-04-02       Impact factor: 2.894

7.  Trends of incidence rate and age at diagnosis for cervical cancer in China, from 2000 to 2014.

Authors:  Xueting Li; Rongshou Zheng; Xuemei Li; Haibin Shan; Qi Wu; Yan Wang; Wanqing Chen
Journal:  Chin J Cancer Res       Date:  2017-12       Impact factor: 5.087

8.  Novel composite drug delivery system as a novel radio sensitizer for the local treatment of cervical carcinoma.

Authors:  Shan Xu; Yu Ying Tang; Yan Xin Yu; Qin Yun; Jing Pin Yang; Heng Zhang; Qiuxia Peng; Xiaoyang Sun; Ling Lin Yang; ShaoZhi Fu; Jing Bo Wu
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

9.  Association of 42 SNPs with genetic risk for cervical cancer: an extensive meta-analysis.

Authors:  Shaoshuai Wang; Haiying Sun; Yao Jia; Fangxu Tang; Hang Zhou; Xiong Li; Jin Zhou; Kecheng Huang; Qinghua Zhang; Ting Hu; Ru Yang; Changyu Wang; Ling Xi; Dongrui Deng; Hui Wang; Shixuan Wang; Ding Ma; Shuang Li
Journal:  BMC Med Genet       Date:  2015-04-15       Impact factor: 2.103

10.  Characteristics and Related Factors of High-Risk Human Papillomavirus Infection in Pregnant Women.

Authors:  Yingying Chen; Jie Dong; Boliang Chu; Xiaoxing Zhang; Xiaofang Ru; Yun Chen; Yunyan Chen; Xiaodong Cheng
Journal:  Med Sci Monit       Date:  2021-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.